Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 June 2013Website:
http://www.bluebirdbio.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 23:47:31 GMTDividend
Analysts recommendations
Institutional Ownership
BLUE Latest News
Montreal, Quebec--(Newsfile Corp. - July 3, 2024) - Blue Thunder Mining Inc. (TSXV: BLUE) (the "Company"), announces that its previously announced name change to Mines D'Or Orbec Inc. will be effective on Friday, July 5, 2024. The Company's trading symbol is not being changed and will continue to be BLUE.
Both Top Independent Proxy Advisors Recommend “FOR” Medallion's Nominees and Executive Compensation Both Top Independent Proxy Advisors Recommend “FOR” Medallion's Nominees and Executive Compensation
NEW YORK , May 30, 2024 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE: OWL) today announced the pricing of the offering of $250,000,000 of 6.250% Senior Notes due 2034 (the "notes") by Blue Owl Finance LLC, its indirect subsidiary, at an issue price of 100.355%, plus accrued interest, if any, from April 18, 2024. The notes are being offered as additional notes under the same indenture as the previously issued $750,000,000 aggregate principal amount of its 6.250% Senior Notes due 2034 and will be treated as a single series with such previously issued senior notes.
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. “We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets wil.
NEW YORK , May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of bluebird bio investors who were adversely affected by alleged securities fraud between April 24, 2023 and December 8, 2023.
NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
BENSALEM, Pa. , May 22, 2024 /PRNewswire/ -- Law Offices of Howard G.
NEW YORK, NY / ACCESSWIRE / May 20, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80689&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / May 19, 2024 / If you experienced a loss on your investment in bluebird bio, Inc. (NASDAQ:BLUE) and are interested in exploring a potential recovery under federal securities laws, please visit the following link for additional details: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80646&wire=1 or reach out to Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for alleged violations of securities laws. Investors who bought the Company's securities between April 24, 2023 and December 8, 2023 (the "Class Period") are advised to contact the firm before May 28, 2024.
What type of business is bluebird bio?
bluebird bio, Inc is a biotechnology company engaged in research, development, and commercialization of gene therapies for severe genetic diseases and cancer. The company was founded in 1992. The corporate headquarters is located in Cambridge, Massachusetts. The European headquarters is in Zug, Switzerland. The developments of bluebird bio Inc. are based on gene therapy. The company's oncology programs focus on developing new methods of immunotherapy based on T-cell therapy, including chimeric antigen receptor T-cell therapy and T-cell receptor therapy. The company has created an integrated product platform with broad therapeutic potential for multiple indications.
What sector is bluebird bio in?
bluebird bio is in the Healthcare sector
What industry is bluebird bio in?
bluebird bio is in the Biotechnology industry
What country is bluebird bio from?
bluebird bio is headquartered in United States
When did bluebird bio go public?
bluebird bio initial public offering (IPO) was on 19 June 2013
What is bluebird bio website?
https://www.bluebirdbio.com
Is bluebird bio in the S&P 500?
No, bluebird bio is not included in the S&P 500 index
Is bluebird bio in the NASDAQ 100?
No, bluebird bio is not included in the NASDAQ 100 index
Is bluebird bio in the Dow Jones?
No, bluebird bio is not included in the Dow Jones index
When does bluebird bio report earnings?
The next expected earnings date for bluebird bio is 08 August 2024